US › Healthcare

Kiora Pharmaceuticals Inc (KPRX)

US · Healthcare · Biotechnology

$2.47-4.63%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-2.4M
Profit YoY
-10.3%
EPS
$-0.58
EPS estimate
$-0.71

EPS came in at -0.58 against a street estimate of -0.71 — a beat of 18.3%.

Key statistics

Market cap
$11.3M
Forward P/E
2.4
P/B
0.81
Book value
$3.49
EPS (TTM)
$-2.70
52-week high
$3.01
52-week low
$1.76
50-day MA
$2.59
200-day MA
$2.31
Beta
-0.39

Analyst view

Analysts rate Kiora Pharmaceuticals Inc a buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $12.00.

Shareholding

Insiders
3.08%
Institutions
28.92%

Largest institutional holders

FundStake
ADAR1 Capital Management LLC3.79%
Citadel Advisors Llc1.12%
Geode Capital Management, LLC1.08%
Vanguard Capital Management, LLC0.45%
XTX Topco Ltd0.33%
Vanguard Fiduciary Trust Co0.29%
TWO SIGMA SECURITIES, LLC0.27%
Morgan Stanley - Brokerage Accounts0.03%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kiora Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.